BUNNIK, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (AP) for inflammatory indications is pleased to announce that the first subjects have entered a Phase I trial of its recombinant AP (recAP) to treat Acute Kidney Injury (AKI).
Help employers find you! Check out all the jobs and post your resume.
